Since the expression of MCL-1 in triple negative breast cancer is high, the ability of ChPL to decrease Mcl-1 levels in MDA-MB-468 cells points to its promising potential in breast cancer treatment. This evidence concerns the gene MCL1 and breast carcinoma.